Medicine pack check sheet

Source-linked reading points

• PAXLOVID is a co-packaged two-ingredient product. Component names, milligram markings or tablet appearance on the pack do not justify self-separating, making up, substituting or adjusting one part with another medicine at home; have the exact prescription, actual pack and current label reviewed by a pharmacist or prescribing team.
• The page image corresponds only to one U.S. co-packaged panel, NDC 0069-5045-06. The label also contains product information for different renal circumstances; the same brand, similar colour or nirmatrelvir/ritonavir wording does not establish that two packs or their contents can be self-interchanged.
• The U.S. label has a prominent warning about significant drug interactions: ritonavir in PAXLOVID can strongly alter exposure to certain co-medications and may lead to serious, life-threatening or fatal events. Before and during use, have a clinician or pharmacist review every prescription medicine, OTC product and herbal/supplement product item by item; do not self-stop, reduce, increase or separate any long-term medicine because of a webpage, package or another person's experience.
• With breathing difficulty, swelling of the face/lips/tongue, difficulty swallowing, severe rash or another acute serious concern, use local emergency medical support immediately. Questions about COVID-19 symptoms, suitability, timing, kidney function, liver function or interactions still require the local care team to use the exact diagnosis, tests and complete medicine list.